報價延遲最少15分鐘:2025/07/01 17:14 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.05 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.27/-0.94
|
|
企業價值
121.25M
|
| 資產負債 |
|
每股賬面淨值
0.10
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/07/01 17:14 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally. |